Alnylam Pharmaceuticals (LTS:0HD2) Inventories, Other: $97 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
65 GF Score
Price $264.24
GF Value $533.28
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alnylam Pharmaceuticals Inventories, Other?

Alnylam Pharmaceuticals LTS:0HD2 -0.10% 65 Inventories, Other is $97 Mil as of Jun. 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 65/100 and a GF Value™ of $533.28 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Alnylam Pharmaceuticals's other inventories for the quarter that ended in Jun. 2026 was $97 Mil.

Alnylam Pharmaceuticals's quarterly other inventories increased from Dec. 2025 ($83 Mil) to Mar. 2026 ($84 Mil) and increased from Mar. 2026 ($84 Mil) to Jun. 2026 ($97 Mil).

Alnylam Pharmaceuticals's annual other inventories declined from Dec. 2023 ($89 Mil) to Dec. 2024 ($79 Mil) but then increased from Dec. 2024 ($79 Mil) to Dec. 2025 ($83 Mil).

Alnylam Pharmaceuticals Inventories, Other Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Inventories, Other Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 128.96 89.15 78.51 82.72

Alnylam Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.69 75.38 82.72 84.03 97.11
LTS:0HD2
65GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Inventories, Other is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Frequently Asked Questions Learn more about Inventories, Other →
What does a Inventories, Other of $97 Mil mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Inventories, Other of $97 Mil as of Jun. 2026. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Inventories, Other too high?
Alnylam Pharmaceuticals' current Inventories, Other is $97 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Inventories, Other compare to RPRX and INSM?
Alnylam Pharmaceuticals' Inventories, Other of $97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Other for a Biotechnology company?
A good Inventories, Other depends on the Biotechnology industry context. However, Inventories, Other should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Other mean?
A high Inventories, Other can signal that a stock is expensive relative to its fundamentals. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Inventories, Other is $97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $533.28, compared to a current price of $264.24 — trading 50.5% below its estimated fair value. The current Inventories, Other is $97 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Other calculated?
Inventories, Other is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Inventories, Other is $97 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $264.24 is trading 50.5% below its estimated GF Value™ of $533.28. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Inventories, Other: $97 Mil
  • GF Value™: $533.28 vs. price of $264.24 (50.5% below fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
65GF Score

Get the complete analysis for LTS:0HD2

Inventories, Other is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$264.24
Price
$533.28
GF Value